Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study.

MLA

Brodowicz, Thomas, et al. “Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study.” Cancers, vol. 12, no. 12, Dec. 2020. EBSCOhost, https://doi.org/10.3390/cancers12123746.

APA

Brodowicz, T., Liegl-Atzwanger, B., Penel, N., Mir, O., Blay, J.-Y., Kashofer, K., Le Cesne, A., Decoupigny, E., Wallet, J., Hamacher, R., & Deley, M.-C. L. (2020). Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study. Cancers, 12(12). https://doi.org/10.3390/cancers12123746

Chicago

Brodowicz, Thomas, Bernadette Liegl-Atzwanger, Nicolas Penel, Olivier Mir, Jean-Yves Blay, Karl Kashofer, Axel Le Cesne, et al. 2020. “Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study.” Cancers 12 (12). doi:10.3390/cancers12123746.